We studied the potential of CTNS mRNA therapy to ameliorate cystinosis, a monogenic lysosomal storage disorder having a well-defined phenotype, presenting with cystine accumulation and both podocyte and proximal tubular dysfunction in the kidney. Here, CTNS is linked to cystinosis.